12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Arikace: FDA hold

FDA placed a clinical hold on planned Phase III trials of Arikace following interim data from 2-year rat inhalation carcinogenicity study of the lung infection candidate. Insmed did not disclose details of the data. FDA requested additional data from the rat...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >